Enterprise Value
288.3M
Cash
18.4M
Avg Qtr Burn
N/A
Short % of Float
0.01%
Insider Ownership
0.14%
Institutional Own.
13.21%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eblasakimab (ASLAN004) (IL-13Ra1 inhibitor) Details Atopic dermatitis | Phase 2b Update | |
Eblasakimab Details Atopic dermatitis | Phase 2 Data readout | |
Farudodstat (ASLAN003) (DHODH inhibitor) Details Autoimmune disease, Alopecia areata | Phase 2a Data readout |